secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001213900-23-040217
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q1 net loss $14.6M ($0.97/sh) vs $3.5M loss YoY; cash $24.3M from $30M upfront financing
--------------------------------------------------------------------------------

- Net loss of $14.6M ($0.97/sh) compared to $3.5M ($0.24/sh) in Q1 2022; includes $10.4M change in warrant liability.
- Licensing revenue $0.7M from Lotus Pharma agreement for Renazorb in South Korea signed February 2023.
- Cash and cash equivalents $24.3M (Dec 2022: $0.5M) after $30M upfront from up to $130M private placement.
- Plans to file NDA for Renazorb by Q3 2023 with potential approval and launch in 2024.
- UNI-494 Phase 1 first cohort enrolled; plans to file IND in 2024 for Phase 2 trial in AKI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/0001213900-23-040217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023040217/ea178564-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-040217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer